KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Total Non-Current Liabilities (2020 - 2025)

AbCellera Biologics (ABCL) has disclosed Total Non-Current Liabilities for 6 consecutive years, with $323.2 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Total Non-Current Liabilities rose 37.41% year-over-year to $323.2 million, compared with a TTM value of $323.2 million through Sep 2025, up 37.41%, and an annual FY2024 reading of $227.9 million, up 5.12% over the prior year.
  • Total Non-Current Liabilities was $323.2 million for Q3 2025 at AbCellera Biologics, down from $328.0 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $328.0 million in Q2 2025 and bottomed at $83.0 million in Q1 2021.
  • Average Total Non-Current Liabilities over 5 years is $207.1 million, with a median of $216.8 million recorded in 2023.
  • The sharpest move saw Total Non-Current Liabilities skyrocketed 140.66% in 2021, then rose 3.45% in 2024.
  • Year by year, Total Non-Current Liabilities stood at $172.2 million in 2021, then increased by 9.96% to $189.3 million in 2022, then grew by 14.5% to $216.8 million in 2023, then rose by 5.12% to $227.9 million in 2024, then soared by 41.82% to $323.2 million in 2025.
  • Business Quant data shows Total Non-Current Liabilities for ABCL at $323.2 million in Q3 2025, $328.0 million in Q2 2025, and $245.8 million in Q1 2025.